Nanolek

What Nanolek does

Nanolek LLC is a privately held Russian full-cycle biopharmaceutical manufacturer founded in 2011 and headquartered in Moscow, with primary manufacturing at the Biomedical Complex (BMK) in Kirov region. The company operates GMP-compliant production spanning antigen biosynthesis, recombinant vaccine manufacturing using yeast-based producer strains, finished dosage form fill-finish, and quality control, supplying Russia's National Immunization Schedule and Vital and Essential Drugs list. Its commercial portfolio includes seven vaccines (Pentaxim, MenQuadfi, Polimilex, PolyovakSin, Cegardex HPV, plus pipeline varicella and 23-valent pneumococcal candidates), three oncology products (Brukinsa/zanubrutinib, Tepadina, Lomustin), and orphan-disease therapies (Hunterase, Hunterase Neuro, and the in-licensed Armocibart for hemophilia).

Nanolek earns revenue primarily through Russian federal and regional government tenders — 23 federal auctions across 88 regions and 193 regional auctions across 55 regions — supplemented by a 49-distributor network and exclusive distribution agreements with international partners including Merck (cardiovascular and diabetes, 10-year technology transfer), Sanofi (Pentaxim, Menactra localization), BeiGene (Brukinsa), GC Biopharma (Hunterase franchise), and Suzhou Alphamab (Armocibart). Pricing is set through competitive tendering under government regulation, with RUB 28.7B in 2025 revenue (14% YoY growth, 20% CAGR 2020–2024) and a top-10 ranking in Russia's pharmaceutical tender market. The company's competitive position rests on domestic import-substitution policy, RUB 15B+ in state-backed and Gazprombank-financed capacity expansion, patent-protected HPV technology developed with NPK Combiotech, and exclusive EAEU/CIS commercialization rights for partnered assets.

In January 2025 ownership restructured when K2 Group divested its 50% stake to private entrepreneurs Gennady Schweigert and Pavel Mileiko, and Evgeny Barinov assumed the General Director role. The company has 800+ employees across Moscow and Kirov, an in-house R&D Center relocated to BMK in 2024, and an explicit export strategy for the Cegardex HPV vaccine under the "Made in Russia" national brand.

Name

Nanolek

Legal name

ООО «Нанолек» (Nanolek LLC)

Website

https://nanolek.ru

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Nanolek is a Russian biopharmaceutical manufacturer founded in 2011 that produces vaccines (HPV, meningococcal, polio, pentavalent), oncology therapies, and orphan-disease drugs for Russia's National Immunization Schedule and broader Eurasian markets through government tenders and partnerships with Merck, Sanofi, BeiGene, and GC Biopharma.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccines & Public Health Product Distribution (CRAOAHAI)

Keywords

• Vaccine manufacturing
• Biopharmaceutical production
• Recombinant vaccines
• Orphan disease therapies
• Oncology drugs

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Vaccine Sales to Government: Primary revenue stream from supplying pediatric and adult vaccines for Russia's National Immunization Schedule through federal and regional government tenders. Products include Pentaxim, MenQuadfi, Polymilex, PolyovakSin, Cegardex, and Pneumotex.
2. Specialized Therapy Drugs: Revenue from oncology drugs (Brukinsa, Tepadina, Lomustin) and orphan disease treatments (Hunterase, Hunterase Neuro) sold through government procurement and commercial channels.
3. Technology Transfer and Localization: Revenue from partnerships with international companies for technology transfer, localization, and contract manufacturing of pharmaceutical products (Merck, Sanofi, BeiGene).

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Nanolek manufactures and supplies vaccines and biopharmaceutical products through full-cycle production (from antigen synthesis to finished dosage form) at its GMP-compliant Biomedical Complex in Kirov Region, Russia. The portfolio includes pediatric and adult vaccines for the Russian National Immunization Schedule, oncology drugs, and enzyme replacement therapies for rare diseases, distributed primarily through government tenders and a network of distributors across Russia and EAEU countries.

Product overview

Nanolek is a Russian biopharmaceutical company offering a diversified portfolio of 7 vaccines and specialized therapy drugs for oncology and orphan diseases. The vaccine portfolio includes pediatric immunizations (Pentaxim, Polimilex, PolyovakSin, MenQuadfi) and the groundbreaking Cegardex, Russia's first domestically produced quadrivalent HPV vaccine. The oncology portfolio features Brukinsa for B-cell malignancies, along with Tepadina and Lomustin. The orphan drug portfolio includes Hunterase and the innovative Hunterase Neuro with intracerebroventricular administration for neurological manifestations of Hunter syndrome. The company operates an innovative manufacturing facility in Kirov region producing medicines to global GMP standards.

Differentiator

Problem solved

Functional benefit

Brands

• Cegardex® (Цегардекс): Quadrivalent recombinant HPV vaccine for prevention of HPV types 6, 11, 16, 18
• MenQuadfi® (МенКвадфи)
• Pentaxim® (Пентаксим)
• Polymilex® (Полимилекс)
• PolyovakSin® (ПолиовакСин)
• Brukinsa® (Брукинза)
• Hunterase® (Хантераза)
• Hunterase Neuro® (Хантераза Нейро)
• Tepadina (Тепадина)
• Lomustin (Ломустин)

Products and services

• Cegardex (Цегардекс) Quadrivalent recombinant vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18. First domestically produced HPV vaccine in Russia with full-cycle production. Developed in partnership with NPK Combiotech; technology protected by patents in the Russian Federation. Approved for adults (March 2025) and children aged 9-17 (January 2026); included in interchangeable medicines list with Gardasil (April 2026).
• MenQuadfi (МенКвадфи) Quadrivalent polysaccharide conjugate vaccine for prevention of meningococcal infection caused by serogroups A, C, W, Y. Part of the National Immunization Schedule supply.
• Pentaxim (Пентаксим) Combined vaccine for prevention of diphtheria, tetanus, pertussis (acellular), poliomyelitis (inactivated), and Haemophilus influenzae type b infection. Localized and produced under Sanofi partnership for the Russian National Immunization Schedule.
• Polimilex (Полимилекс) Inactivated vaccine for prevention of poliomyelitis, part of National Immunization Schedule supply.
• PolyovakSin (ПолиовакСин) Cultured purified concentrated inactivated liquid polio vaccine from attenuated Sabin strains.
• Brukinsa (Брукинза) Selective low-molecular Bruton's tyrosine kinase (BTK) inhibitor (zanubrutinib) for treatment of B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma. Distributed under exclusive partnership with BeiGene across Russia and EAEU; included in Vital and Essential Drugs (VED) list (January 2025).
• Tepadina (Тепадина) Antitumor alkylating agent from the nitrogen mustard group (thiotepa) used in oncology treatment regimens.
• Lomustin (Ломустин) Antitumor alkylating agent from the nitrosourea group used in oncology treatment.
• Hunterase (Хантераза) Recombinant human iduronate-2-sulfatase (idursulfase beta) for long-term enzyme replacement therapy in patients with Hunter syndrome (mucopolysaccharidosis type II). Distributed under partnership with GC Biopharma since 2018.
• Hunterase Neuro (Хантераза Нейро) Intracerebroventricular formulation of idursulfase beta for treatment of neurological manifestations of Hunter syndrome (MPS II), administered via Ommaya reservoir. Innovative enzyme replacement therapy distributed under partnership with GC Biopharma.

Quantifiable outcome

• 15 million children in Russia vaccinated with Nanolek-produced vaccines
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Suzhou Alphamab Co., Ltd.coreStrategic or Co-development Partner · 17 June 2026Strategic cooperation to commercialize Armocibart (subcutaneous drug for hemophilia A/B prevention) in Russia, EAEU countries, Azerbaijan, and Uzbekistan. Nanolek receives exclusive rights to registration, promotion, and commercialization.
• Government of Kirov RegioncoreStrategic or Co-development Partner · 19 May 2025Cooperation agreement for social and economic development including biotechnology, social infrastructure, employment, and education. Includes action plan for Orichevsky district development with RUB 4 million annual social project funding.
• SanoficoreStrategic or Co-development Partner · 1 January 2022Partnership for Pentaxim pentavalent vaccine and Menactra meningococcal vaccine localization and production at Nanolek facility in Russia.
• NPK CombiotechcoreStrategic or Co-development Partner · 1 January 2022Partnership for development of Russia's first HPV vaccine Cegardex. Manufacturing technology protected by patents in Russian Federation.
• BeiGenecoreStrategic or Co-development Partner · 1 January 2020Strategic partnership for Brukinsa (zanubrutinib) distribution in Russia and EAEU countries. Includes exclusive rights for distribution, promotion, pharmacovigilance, secondary packaging and quality control.
• MerckcoreStrategic or Co-development Partner · 1 January 201510-year strategic partnership (2015-2025) for technology transfer and localization of cardiovascular and diabetes medications. Produced 10+ billion tablets at Kirov facility. Full technology transfer including quality control methods and project management best practices.
• GC Biopharma (South Korea)coreStrategic or Co-development Partner · 1 January 20159-year partnership for orphan disease therapies. Introduced Hunterase (2018) and Hunterase Neuro (2024) for Hunter syndrome treatment. Includes varicella vaccine development and clinical trials in Russia.
• Vyatka State UniversityminorStrategic or Co-development Partner · 1 January 2015Educational partnership for training biotechnology specialists. Over 70 university graduates employed at Biomedical Complex. Joint educational project 'Research Track with Nanolek' for student research experience.

Scale indicators17 records

Recent moves10 records

Expansion highlights6 records

Market position

Strengths1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/nanolek
• LinkedInlinkedin.com/company/nanolek

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanolek